Source: Zoetis, Inc. submitted to NRP
EXPERIMENTAL BM86-BASED VACCINE FOR THE CATTLE FEVER TICK ERADICATION PROGRAM
Sponsoring Institution
Agricultural Research Service/USDA
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
0423237
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Jul 1, 2012
Project End Date
Aug 31, 2016
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
Zoetis, Inc.
333 Portage Road
Kalamazoo,MI 49007-0199
Performing Department
(N/A)
Non Technical Summary
(N/A)
Animal Health Component
0%
Research Effort Categories
Basic
90%
Applied
0%
Developmental
10%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3123120104048%
3123310108032%
3123410113020%
Goals / Objectives
Generate research data through collaborative effort: obtain limited use permit for experimental Bm86-based veterinary biological product from APHIS Center for Veterinary Biologics, and perform Cattle Fever Tick Eradication Program.
Project Methods
Studies will be planned and executed according to APHIS Center for Veterinary Biologics General Licensing Considerations for Efficacy Studies. Cooperator will prepare and provide the ARS two experimental vaccine formulations containing the antigen Bm86 for efficacy testing. Each of the two experimental Bm86-based vaccines will be tested for efficacy against Rhipicephalus annulatus and R. microplus by the Cattle Fever Tick Research Laboratory. Studies will be reported according to APHIS Center for Veterinary Biologics General Licensing Considerations for Efficacy Studies.

Progress 10/01/12 to 09/30/13

Outputs
Progress Report Objectives (from AD-416): Generate research data through collaborative effort: obtain limited use permit for experimental Bm86-based veterinary biological product from APHIS Center for Veterinary Biologics, and perform Cattle Fever Tick Eradication Program. Approach (from AD-416): Studies will be planned and executed according to APHIS Center for Veterinary Biologics General Licensing Considerations for Efficacy Studies. Cooperator will prepare and provide the ARS two experimental vaccine formulations containing the antigen Bm86 for efficacy testing. Each of the two experimental Bm86-based vaccines will be tested for efficacy against Rhipicephalus annulatus and R. microplus by the Cattle Fever Tick Research Laboratory. Studies will be reported according to APHIS Center for Veterinary Biologics General Licensing Considerations for Efficacy Studies. Studies were completed using two BM86-based vaccine formulations on both R. annulatus and R. micorplus. Very high efficacy was observed in both formulations against R. annulatus (>99%) and good efficacy was observed for R. microplus (54% and 65% for formulation 1 and 2, respectively). Randomly selected animals were necropsied,and all data were sent to CVB for consideration. Plans are now underway for a field safety experiment, followed by vaccination of all cattle (>10,000 head) in the Cattle Fever Tick Eradication Zone within 6 months. This represents the first non- chemical control technique used in the 107-year-old Cattle Fever Tick Eradication Program and represents a great step to create an integrated and sustainable approach to maintain the eradication of cattle fever tick from the USA.

Impacts
(N/A)

Publications